


# Scaffolds for Alternative DELivery



## Nanofitin<sup>®</sup>-based drug in Inflammatory Bowel Disease (IBD)

- A project supported by the European Commission through the Seventh Framework Programme (FP7)
- Research on first-in-class generation of non-parenteral biotherapeutics
- Clinically validated target chosen: TNF $\alpha$
- New class of non-antibody affinity ligands able to selectively bind a wider range of targets
- Nanofitin<sup>®</sup> characteristics:
  - Small size (optimal tissue penetration)
  - Resistance to pH and to human intestinal fluids (long-half-life in digestive track)
  - High affinity (low effective concentration needed)
  - Strong potential for reduced immunogenicity compared to current biologics

